Skip to main
XNCR
XNCR logo

Xencor (XNCR) Stock Forecast & Price Target

Xencor (XNCR) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 13%
Buy 75%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

The financial outlook for Xencor Inc is optimistic due to the anticipated revenue growth from existing partnerships and a promising pipeline of antibody product candidates, particularly XmAb819, which has shown initial success and clear clinical benefit. The company’s technology platform and collaborations enhance its valuation, suggesting that market opportunities in both oncology and autoimmune indications could drive substantial future revenues. Furthermore, recent share price volatility is viewed as a strategic entry point for investors, with a strong risk/reward profile anticipated based on de-risking mechanisms and potential market successes yet to be fully realized in Xencor's stock valuation.

Bears say

Xencor Inc's negative outlook is influenced by the potential for limited durability and safety issues associated with its pipeline candidate XmAb819, which could lead to a significant decline in share value. The company's recent setbacks, including the discontinuation of AGS-16C3F due to lack of efficacy against existing treatments and the elevated rates of cytokine release syndrome (CRS) in clinical trials, highlight significant operational risks. Additionally, ongoing challenges in achieving regulatory approval, meeting sales expectations, and securing expected royalties from partnerships further complicate the company's financial trajectory.

Xencor (XNCR) has been analyzed by 8 analysts, with a consensus rating of Buy. 13% of analysts recommend a Strong Buy, 75% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Xencor and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Xencor (XNCR) Forecast

Analysts have given Xencor (XNCR) a Buy based on their latest research and market trends.

According to 8 analysts, Xencor (XNCR) has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Xencor (XNCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.